MXPA02010430A - Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. - Google Patents

Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.

Info

Publication number
MXPA02010430A
MXPA02010430A MXPA02010430A MXPA02010430A MXPA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A MX PA02010430 A MXPA02010430 A MX PA02010430A
Authority
MX
Mexico
Prior art keywords
treating
disease
neurodegenerative diseases
treatment
amino acid
Prior art date
Application number
MXPA02010430A
Other languages
English (en)
Inventor
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA02010430A publication Critical patent/MXPA02010430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La invencion se relaciona a inhibidores BCAT y al uso de los mismos para tratar o prevenir pérdida neuronal asociada con apoplejía, isquemia, trauma por SNC, hipoglicemia y cirugía, así como para tratar enfermedades neurodegenerativas incluyendo enfermedad de Alzheimer, esclerosis lateral amiotrofica, enfermedad de Huntington y síndrome de Down, para tratar o prevenir las consecuencias adversas de la sobreestimulacion de Ios aminoácidos excitadores, tratar ansiedad, psicosis, convulsiones, pérdida de audicion inducida por antibioticos aminoglicosidos, migrafia, dolor cronico, dolor neuropático, enfermedad de Parkinson, retinopatía diabética, glaucoma, retinitis por CMV, incontinencia urinaria, tolerancia o retiro de opioide exogeno y anestesia inducida, así como para cognicion incrementada.
MXPA02010430A 2001-11-27 2002-10-22 Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. MXPA02010430A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33359301P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
MXPA02010430A true MXPA02010430A (es) 2003-06-02

Family

ID=23303445

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010430A MXPA02010430A (es) 2001-11-27 2002-10-22 Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.

Country Status (10)

Country Link
US (1) US6632831B2 (es)
EP (1) EP1314426B1 (es)
JP (1) JP2003183264A (es)
AT (1) ATE317696T1 (es)
AU (1) AU2002351011A1 (es)
BR (1) BR0206327A (es)
CA (1) CA2412624A1 (es)
DE (1) DE60209192T2 (es)
MX (1) MXPA02010430A (es)
WO (1) WO2003045384A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100384828C (zh) * 2005-05-08 2008-04-30 山东大学 (z)-5-[[(3,5-二叔丁基)-4-羟基苯基]亚甲基]-2-亚氨基-4-噻唑啉酮甲磺酸盐的制备方法
EP2481801A1 (en) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775677A (en) * 1985-05-13 1988-10-04 Warner-Lambert Company [3-substituted-2-(substituted imino)-4-oxo-5-thiazolidinylidene]acetic acids having activity as leukotriene antagonists
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5554767A (en) * 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
JPH07285952A (ja) * 1994-04-08 1995-10-31 Fujisawa Pharmaceut Co Ltd 新規複素環誘導体
KR20010101811A (ko) * 1999-12-08 2001-11-14 웨이크 포리스트 유니버시티 분지쇄 아미노산 의존성 아미노트랜스페라제 억제제 및당뇨병성 망막증 치료에서의 그들의 용도
MXPA03001277A (es) * 2000-09-19 2004-07-30 Warner Lambert Co Inhibidores de aminotransferasa dependientes de aminoacido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas.

Also Published As

Publication number Publication date
EP1314426B1 (en) 2006-02-15
BR0206327A (pt) 2003-11-18
DE60209192T2 (de) 2006-11-16
EP1314426A9 (en) 2003-09-17
CA2412624A1 (en) 2003-05-27
EP1314426A1 (en) 2003-05-28
DE60209192D1 (de) 2006-04-20
US6632831B2 (en) 2003-10-14
US20030162779A1 (en) 2003-08-28
AU2002351011A1 (en) 2003-06-10
WO2003045384A1 (en) 2003-06-05
JP2003183264A (ja) 2003-07-03
ATE317696T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
MXPA02010231A (es) Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
IL168365A (en) Use of a rasagaline with or without riluzole for preparing a medicament for treating amyotrophic lateral sclerosis
HK1052921A1 (en) Aminoadamantane derivatives as therapeutic agents .
ZA97991B (en) Novel cyclic amino acids as pharmaceutical agents.
IL125544A0 (en) Novel substituted cyclic amino acids as pharmaceutical agents
ZA972199B (en) Novel bridged cyclic amino acids as pharmaceutical agents.
EP1390491A4 (en) METHOD OF TREATING NEURODEGENERATIVE, PSYCHIATRIC AND OTHER DISEASES WITH DEACETYLASE INHIBITORS
EP1021418A4 (en) SUBSTITUTED 2,3-BENZODIAZEPINE-4-ONE AND THEIR USE
ATE280154T1 (de) Verzweigte alkylpyrrolidin-3-carbonsäuren
NZ276892A (en) Quinoxalinedione derivatives, preparation and use in pharmaceutical compositions thereof
EP1983000A3 (en) Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
TW200733976A (en) Method for the treatment of cognitive dysfunction
MXPA03001277A (es) Inhibidores de aminotransferasa dependientes de aminoacido de cadena ramificada y su uso en el tratamiento de enfermedades neurodegenerativas.
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
WO1995018616A3 (en) 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
AU4673300A (en) Amino heterocycles useful as pharmaceutical agents
MXPA02010430A (es) Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
HUT64841A (en) Process and composition for treating eyes
MX2021013070A (es) Farmaco terapeutico para discinesia.
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
NO20045089L (no) Substituerte aminoalkanfosfonsyrer for behandling av neuropatisk smerte, affektive og oppmerksomhetsforstyrrelser, schizofreni, tinnitus, myopi og andre okulaere lidelser
WO2023107630A3 (en) Amino alcohol compounds and uses thereof